(Q47640667)

4 February 2018

title

The hope but challenge for developing a vaccine that might control malaria (English)

1 reference

4 February 2018

0 references

1 reference

1

Michael F Good

1 reference

4 February 2018

language of work or name

English

0 references

publication date

1 April 2009

1 reference

4 February 2018

European Journal of Immunology

published in

1 reference

4 February 2018

volume

39

1 reference

4 February 2018

issue

4

1 reference

4 February 2018

page(s)

939-943

1 reference

4 February 2018

Vaccines for preventing malaria (SPf66)

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

A retrospective examination of secondary sporozoite- and trophozoite-induced infections with Plasmodium falciparum: development of parasitologic and clinical immunity following secondary infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

Plasmodium yoelii can ablate vaccine-induced long-term protection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

The T cell response to the malaria circumsporozoite protein: an immunological approach to vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

Expression of Plasmodium falciparum blood-stage antigens in Escherichia coli: detection with antibodies from immune humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

7 January 2021

Cloning and expression in E. coli of the malarial sporozoite surface antigen gene from Plasmodium knowlesi

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

7 January 2021

Structure of the Gene Encoding the Immunodominant Surface Antigen on the Sporozoite of the Human Malaria Parasite Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

7 January 2021

DNA Cloning ofPlasmodium falciparumCircumsporozoite Gene: Amino Acid Sequence of Repetitive Epitope

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

7 January 2021

Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

7 January 2021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

7 January 2021

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

7 January 2021

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

7 January 2021

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

7 January 2021

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

7 January 2021

Human T-cell recognition of the circumsporozoite protein of plasmodium falciparum: Immunodominant T-cell domains map to the polymorphic regions of the molecule

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

7 January 2021

Natural amino acid polymorphisms of the circumsporozoite protein of Plasmodium falciparum abrogate specific human CD4+ T cell responsiveness

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

7 January 2021

Inability of Malaria Vaccine to Induce Antibodies to a Protective Epitope Within Its Sequence

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

7 January 2021

A hopeful beginning for malaria vaccines

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

7 January 2021

Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

7 January 2021

Human malaria parasites in continuous culture

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

7 January 2021

An Effective Immunization of Experimental Monkeys Against a Human Malaria Parasite, Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

7 January 2021

In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

7 January 2021

A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

7 January 2021

Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

7 January 2021

A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

7 January 2021

Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

7 January 2021

Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

7 January 2021

Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuatedPlasmodium falciparumsporozoite vaccine

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

7 January 2021

Genetically modified Plasmodium parasites as a protective experimental malaria vaccine

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

7 January 2021

Gene disruption of Plasmodium falciparum p52 results in attenuation of malaria liver stage development in cultured primary human hepatocytes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

7 January 2021

Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

7 January 2021

Heterologous immunity in the absence of variant-specific antibodies after exposure to subpatent infection with blood-stage malaria

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

7 January 2021

Malaria vaccines: the case for a whole-organism approach

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

7 January 2021

Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo-controlled field trial in an endemic area of Ecuador

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

7 January 2021

Transcriptionally active PCR for antigen identification and vaccine development: in vitro genome-wide screening and in vivo immunogenicity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

7 January 2021

Research toward malaria vaccines

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939390

7 January 2021

Identifiers

DOI

10.1002/EJI.200939390

1 reference

4 February 2018

1 reference

4 February 2018